Publications by authors named "Melanie J Russell"
Article Synopsis
- - The study aimed to analyze real-world treatment persistence rates of disease-modifying therapies (DMTs) for individuals with multiple sclerosis (MS), examining factors that lead to discontinuation of these treatments.
- - Data from 4,366 patients with relapse-onset MS were collected from 13 specialist centers in the UK, finding a median persistence of 4.3 years on any DMT, with adverse events and lack of efficacy being the top reasons for stopping treatment.
- - Results indicated that immune reconstituting therapies like alemtuzumab may provide more prolonged DMT options compared to traditional therapies, emphasizing the importance of understanding DMT persistence for better treatment strategies.
